All In Biotech

Investigational drug · Phase 2

FT819

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Lupus Nephritis, Systemic Lupus Erythematosus, SLE - Systemic Lupus Erythematosus.

Phase 2

Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

3

Any phase or sponsor naming "FT819"

First trial start

2026

Jul 27, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "FT819", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Lupus Nephritis
  • Systemic Lupus Erythematosus
  • SLE - Systemic Lupus Erythematosus
  • Lupus Nephritis - WHO Class III
  • Lupus Nephritis - WHO Class IV

Approved drugs for the same conditions: Lupus (SLE) · Immunology and inflammation · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "FT819" as an intervention, largest first.

All trials
  • Fate TherapeuticsIndustry

    NCT06308978 · 244 participants (planned) · Start Mar 28, 2024 · Primary completion Sep 30, 2027

    Drug: FT819; Fludarabine and 2 more · For: Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV); Idiopathic Inflammatory Myositis (IIM); Systemic Sclerosis (SSc) and 2 more

    Sites: Beverly Hills, California; Fullerton, California; Irvine, California · 21 sites in all

  • Fate TherapeuticsIndustry

    NCT04629729 · 54 participants · Start Jul 12, 2021 · Primary completion Jun 18, 2025

    Drug: FT819; Cyclophosphamide and 3 more · For: Lymphoma, B-Cell; Chronic Lymphocytic Leukemia; Precursor B-Cell Acute Lymphoblastic Leukemia

    Sites: Birmingham, Alabama; Phoenix, Arizona; Davis, California · 18 sites in all

  • Fate TherapeuticsIndustry

    NCT07570862 · 53 participants (planned) · Start Jul 27, 2026 · Primary completion Jul 1, 2029

    Drug: FT819 · For: Lupus Nephritis; Systemic Lupus Erythematosus; SLE - Systemic Lupus Erythematosus and 2 more

    Sites: Beverly Hills, California; Fontana, California; Fullerton, California · 12 sites in all

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Lupus Nephritis

  • IanalumabVAY736, VAY736 AIPhase 318 trials

    Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome

  • hUC-MSCsmesenchymal stem cells, MSCPhase 38 trials

    Shenzhen Wingor Biotechnology Co., Ltd. · Knee Osteoarthritis, Crohn&Amp;#39;s, Crohn&Amp;#39;s Disease (CD)

  • PovetaciceptALPN-303Phase 37 trials

    Vertex Pharmaceuticals · Immunoglobulin A Nephropathy, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy

  • Rese-celCABA-201Phase 34 trials

    Cabaletta Bio · Pemphigus Vulgaris, Systemic Sclerosis, Scleroderma

  • Zola-celBMS-986353, CC-97540Phase 33 trials

    Bristol Myers Squibb · Systemic Sclerosis, Lupus Erythematosus, Systemic, Lupus Nephritis

  • rapcabtagene autoleucelYTB323Phase 28 trials

    Novartis · Lupus Nephritis, Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD), ANCA Associated Vasculitis (AAV)

  • UC-MSCRY_SW01 cell, Human umbilical cord mesenchymal stem cellsPhase 28 trials

    Jiangsu Renocell Biotech Company · Acute Respiratory Distress Syndrome, Lupus Nephritis, Spinocerebellar Ataxia Type 1

  • IPG11406Phase 23 trials

    Nanjing Immunophage Biotech Co., Ltd · Lupus Nephritis, Moderately to Severely Active Ulcerative Colitis (UC)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.